Introduction
============

Atherosclerosis is a leading cause of death in developed countries and it is crucial to distinguish the unstable plaques from the stable ones to increase the survival of patients with early intervention [@B1]. The initial abnormality in the pathogenesis of atherosclerotic plaques is the fatty streak, a white/yellow linear discoloration that is visible macroscopically on the endothelial surface of an artery, caused by accumulation of lipids and macrophages. This initial lesion matures into an atherosclerotic plaque with the accumulation of lipid and connective tissue, in particular collagen. As the plaque grows, the vessel expands to preserve the blood flow, a process known as positive remodeling. The artery eventually can expand no farther, and the plaque begins to occlude the lumen of the vessel causing circulatory obstruction [@B2]-[@B4] (**Figure [1](#F1){ref-type="fig"}**). Unstable plaques that are prone to cardiovascular accidents demonstrate a thin fibrous cap, large lipid core, paucity of smooth muscle cells and abundance of inflammatory cells (**Figure [2](#F2){ref-type="fig"}**) [@B5], [@B6].

Clinical imaging of atherosclerosis
===================================

Traditionally atherosclerosis is visualized based on the anatomical changes in the vessel walls such as calcification and stenosis. Many techniques have been used for imaging of atherosclerosis in the clinic, such as X-ray angiography, optical coherence tomography (OCT), intravascular ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), single photon emission computed tomography (SPECT), positron emission tomography (PET), etc. [@B4]. Angiography yields an excellent resolution but it is highly observer dependent and not very reproducible [@B7]-[@B9]. Moreover diffuse arterial narrowing without obvious luminal irregularity can be easily missed in angiographic images [@B10]. Even if angiography could demonstrate the luminal narrowing accurately, it has been documented that acute coronary syndromes often result from plaque rupture at sites with no or only modest luminal narrowing based on angiography [@B11]-[@B13].

Molecular imaging of atherosclerosis
====================================

Many biological changes take place in atherosclerotic plaques preceding the appearance of anatomical disturbances [@B24], [@B25]. Given that a large proportion of people who suffer a sudden cardiac event have no prior symptoms [@B26], it is crucial for diagnostic procedures to go beyond the simple assessment of the vessel lumen to identify rupture-prone vulnerable plaques [@B6]. When compared with traditional methods, molecular imaging approaches have a number of advantages, such as enabling noninvasive study of cells in their natural microenvironment hence providing information on the whole biological process rather than a small part of it. In terms of experimental studies it is possible to perform longitudinal studies in the same animals with molecular imaging techniques, which will reduce the cost and can provide better statistical power.

Since the beginning of the 21^st^ century, the field of molecular imaging has expanded tremendously [@B27]-[@B34]. Many of the preclinical imaging studies focused on atherosclerosis involved the use of MRI and/or optical techniques, for which excellent recent reviews are available [@B4], [@B6], [@B11], [@B35]-[@B37]. A few other imaging techniques have also been employed for imaging of atherosclerosis such as Raman spectroscopy, which measures the light-scattering effects [@B23], [@B38]. In one study, Raman spectroscopy was used for imaging atherosclerosis associated inflammation with protease-activated fluorescent probes (representing capthesin-B and matrix metalloprotease (MMP)-2/9 expression) [@B39].

Molecular vascular imaging with PET can enable early detection of these changes, thereby decreasing the dependence to invasive biopsies or surgical procedures to characterize diseased tissues [@B11], [@B20], [@B23], [@B24], [@B40], [@B41]. PET can detect tracer concentrations in the picomolar range, providing 4-5 mm resolution with clinical PET scanners and 1-2 mm with small animal PET scanners, and has been routinely used in clinical cancer patient management and preclinical research [@B42]-[@B48]. Although there is no optimal PET tracer for routine clinical imaging of atherosclerosis available to date [@B10], various imaging agents have been investigated for PET imaging of atherosclerosis, targeting different components of the atherosclerotic plaque (**Table [1](#T1){ref-type="table"}**).

In this review, we will summarize the targets and tracers used for PET imaging of atherosclerosis in experimental and clinical studies. The targets and pathways that have been investigated to date for PET imaging of atherosclerosis include: glycolysis, cell membrane metabolism (phosphatidylcholine synthesis), integrin α~v~β~3,~ low density lipoprotein (LDL) receptors (LDLr), natriuretic peptide clearance receptors (NPCRs), fatty acid synthesis, vascular cell adhesion molecule-1 (VCAM-1), macrophages, platelets, etc. (**Table [1](#T1){ref-type="table"}**). To create experimental models for atherosclerosis, animals are typically kept on a high fat diet. Commonly used animal models for studying atherosclerosis are: C57BL/6 Apolipoprotein (Apo) E^-/-^mice, C57BL/6 LDL receptor deficient mice (LDLr^-/-^ mice), heterozygous LDL receptor deficient rabbits (LDLr^+/-^ rabbits), and homozygous LDL receptor deficient rabbits (LDLr^-/-^ rabbits) [@B49]-[@B51]. The aorta is typically used as the human coronary artery analog in rodents since the diameter of mouse aorta is \~1 mm, comparable to the size of small arteries in humans [@B11].

PET imaging of atherosclerosis with ^18^F-FDG
=============================================

2-deoxy-2-^18^F-fluoro-D-glucose (^18^F-FDG) is one of the most frequently used PET tracers for in vivo imaging of atherosclerosis [@B4]. Deoxyglucose is a glucose analog that competes with glucose for uptake into metabolically active macrophages in atherosclerotic plaques. After being labeled with ^18^F, the resultant ^18^F-FDG is taken up into metabolically active cells but is not metabolized and thereby accumulates in atherosclerotic plaques (**Figure [3](#F3){ref-type="fig"}A**) [@B4]. More than 15 years ago, studies have demonstrated uptake of ^18^F-FDG in the region of the aortic arch in a rabbit model of atherosclerosis [@B52], while normal rabbits did not show increased uptake above background levels. Ex vivo analysis of the aortic arch confirmed ^18^F-FDG uptake in areas of atherosclerosis that were rich in macrophages. In another early study, Lederman et al. [@B53] documented a 4-fold increase in ^18^F-FDG uptake by atherosclerotic plaques in iliac arteries of New Zealand White rabbits fed with high cholesterol diet.

A number of studies have been reported in patients. Yun et al. [@B10] reported the increased uptake of ^18^F-FDG in 137 consecutive patients correlated with atherogenic risk factors. Among all risk factors, age was found to be the most significant factor. In another study, Rudd et al. [@B54] documented the ability of ^18^F-FDG PET to image inflammation within carotid artery atherosclerotic plaques in 8 patients with symptomatic carotid atherosclerosis, who had experienced a recent carotid territory transient ischemic attack (TIA) and had an internal carotid artery stenosis of at least 70%. Several other clinical studies followed [@B55]-[@B58].

However, in a study carried out by Laurberg et al. [@B59], the authors did not observe increased aortic or carotid tracer accumulation in hypercholesterolemic, ApoE^-/-^ mice. Moreover, Menezes et al. [@B60] retrospectively examined 250 PET/CT images of 50 patients covering a 5 year period and found that they could not reproduce the similar results in subsequent images in patients with initially increased ^18^F-FDG uptake in carotids and the aorta. Therefore, it was concluded that increased ^18^F-FDG uptake in arterial lesions is a transient phenomenon. The discrepancy between the results of these studies and others remains unexplained [@B61], [@B62]. In an interesting report, it was shown that different mechanisms for stimulation of macrophages, smooth muscle cells, and endothelial cells may contribute to increased ^18^F-FDG uptake in atherosclerotic plaques [@B63]. Experimental evidence suggested that hypoxia may play an important role in ^18^F-FDG accumulation in atheromata, which deserves to be investigated in more detail in animal models and clinical settings to further our understanding of the biological mechanisms and significance of ^18^F-FDG uptake in atheromata.

PET imaging of atherosclerosis with radiolabeled choline
========================================================

Choline is taken up into cells by specific transport mechanisms, phosphorylated by choline kinase, metabolized into phosphatidylcholine, and eventually incorporated into the cell membrane [@B61]. Increased uptake of choline has been observed in activated macrophages [@B64], which led to the idea of using radiolabeled choline for PET imaging of atherosclerotic plaques. For example, Matter et al. [@B65] used ^18^F-Choline as the tracer to detect atherosclerotic plaques in ApoE^-/-^ mice and reported superior results when compared with ^18^F-FDG. Laitinen et al. [@B66] observed a high ^11^C-choline uptake in the aortic plaques of atherosclerotic mice deficient for both LDLr and apolipoprotein B48. Kato et al. [@B67] reported an increased ^11^C-choline uptake in vessel walls of 93 consecutive male patients between 60 and 80 years old (**Figure [3](#F3){ref-type="fig"}B**). However, PET tracer uptake and calcification are rarely co-localized. Therefore, it was concluded that ^11^C-choline has the potential to provide information about atherosclerotic plaques independent of calcification measurement.

PET imaging of atherosclerosis targeting integrin α~v~β~3~
==========================================================

Integrin α~v~β~3~ is a cell adhesion molecule expressed by macrophages and endothelial cells in atherosclerotic lesions [@B4]. Laitinen et al. [@B68] evaluated integrin α~v~β~3~ deposition in atherosclerotic plaques in mice with ^18^F-galacto-RGD PET (RGD denotes arginine-glycine-aspartic acid, potent antagonists of integrin α~v~β~3~). They dissected the aorta of mice 2 hours after tracer injection and found that biodistribution of ^18^F-galacto-RGD was higher in the atherosclerotic than in the normal aorta, and ^18^F-galacto-RGD uptake was directly correlated with macrophage density in the plaques. In a previous clinical study, Beer et al. [@B69] investigated the dosimetry of ^18^F-galacto-RGD in 18 human subjects and concluded that it demonstrates high metabolic stability, a favorable biodistribution, and a low radiation dose. Therefore, this tracer can safely be used for noninvasive PET imaging of molecular processes (e.g. atherosclerosis) involving integrin α~v~β~3~.

PET imaging of atherosclerosis with ^18^F-labeled LDL
=====================================================

Oxidation of LDL is regarded as a crucial event in atherogenesis. Langer et al. [@B70] conjugated ^124^I to the scavenger receptor CD68 (soluble CD68-Fc) and used this molecule for the detection of atherosclerotic plaques in wild type or ApoE^-/-^ mice. Since CD68 binds to oxidized LDL (ox-LDL) molecules and mediates their uptake, this tracer could be a useful tool for noninvasive imaging of atherosclerosis. In another study, Pietzsch et al. [@B71] reported PET imaging with ^18^F-labeled native LDL (nLDL) and ox-LDL after injection into male Wistar rats. It was suggested that the use of ^18^F-labeled LDL could be an attractive alternative to iodinated LDL. Future studies are warranted to clarify the potential of radiolabeled LDL for the detection of atherosclerotic changes.

PET imaging of atherosclerosis targeting NPCR
=============================================

Natriuretic peptides (NPs) have potent antiproliferative and antimigratory effects on vascular smooth-muscle cells and participate in vascular remodeling in atherosclerosis. The expression of NPCRs is upregulated both in endothelium and in vascular smooth-muscle cells during the formation of atherosclerotic plaques [@B72]. Liu et al. [@B72] investigated the potential of radiolabeled C-type atrial natriuretic factor (C-ANF) to noninvasively image developing plaque-like lesions. C-ANF was linked with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and labeled with ^64^Cu for noninvasive PET in a hypercholesterolemic rabbit model, which demonstrated that ^64^Cu-DOTA-C-ANF was a promising candidate for PET of NPCR in atherosclerotic plaques (**Figure [3](#F3){ref-type="fig"}C**). In a follow-up study, the same group developed a C-ANF-integrated, ^64^Cu-labeled nanoprobe for in vivo PET imaging of NPCR during angiogenesis in a mouse hindlimb ischemia model [@B73].

PET imaging of atherosclerosis with other tracers
=================================================

In addition to the abovementioned examples, many other tracers have been investigated for imaging of atherosclerosis. Derlin et al. [@B74] used ^11^C-acetate PET/CT for the evaluation of atherosclerotic plaques in 36 patients (**Figure [4](#F4){ref-type="fig"}**). Fatty acids are a common constituent of atherosclerotic plaque and may be synthesized in the plaque itself. Fatty acid synthesis requires acetyl-coenzyme-A (CoA) as a main substrate, which is produced from acetate. Therefore, ^11^C-acetate, just like ^18^F-FDG, can be used as a non-specific tracer for in vivo imaging of atherosclerotic plaques.

VCAM-1 is a monocyte and lymphocyte adhesion factor expressed by endothelial cells under pro-atherogenic conditions [@B75], [@B76]**.**Nahrendorf et al. [@B77] have investigated the potential of VCAM-1 as a target for PET imaging of vulnerable plaques. A tetrameric VCAM-1 affinity peptide (V4), which can be internalized into endothelial cells after VCAM-1 binding, was labeled with ^18^F and tested in atherosclerotic ApoE^-/-^ mice receiving a high-cholesterol diet. The tracer was found to be suitable for noninvasive PET imaging of VCAM-1 in inflammatory atherosclerosis, as well as monitoring the effects of therapeutic intervention. In another study, Nahrendorf et al. [@B78] also reported the use of a ^64^Cu-labeled, dextranated, diethylenetriaminepentaacetic acid (DTPA)-modified magnetofluorescent nanoparticle for imaging of atherosclerotic plaques. The agent was termed ^64^Cu-TNP (i.e. trireporter nanoparticle), where its uptake in atherosclerosis was based on the avidity of lesional macrophages for polysaccharide-containing supramolecular structures. It was found that ^64^Cu-TNP accumulated predominantly in macrophages in atherosclerotic plaques in ApoE^-/-^ mice (**Figure [5](#F5){ref-type="fig"}**).

Silvola et al. [@B79] investigated the uptake of ionic ^68^Ga in atherosclerotic LDLr^-/-^ApoB100/100 mice. PET/CT imaging revealed an elevated ^68^Ga uptake in the aortic atherosclerotic plaques of mice, especially at the sites that are rich in macrophages. Ex vivo biodistribution studies and autoradiography of aortic cryosections confirmed the results of in vivo imaging. However, it was stated that the slow blood clearance may limit the clinical usability of ^68^Ga as a PET tracer for imaging of atherosclerosis. In another study, Yano et al. [@B80] suggested that ^68^Ga-labeled platelets could be useful for PET imaging of thrombosis or atherosclerosis. However, no in vivo studies were carried out, although in vitro labeling of rabbit platelets with ^68^Ga was successful.

Gaemperli et al. [@B81] recently suggested the use of ^11^C-PK11195, a selective ligand of the translocator protein which is highly expressed by activated macrophages, for PET imaging of atherosclerosis. Initial results obtained from 32 patients with carotid stenosis were encouraging. Elmaleh et al. [@B82] evaluated PET imaging with ^18^F-AppCHFppA, a competitive inhibitor of adenosine diphosphate-induced platelet aggregation, to detect atherosclerotic lesions in male New Zealand White rabbits. It was reported that the accumulation of ^18^F-AppCHFppA in macrophage rich atherosclerotic plaques could be quantified noninvasively.

Conclusion and future perspectives
==================================

A wide variety of targets and tracers have been investigated for PET imaging of atherosclerosis, which has significant potential for translation and future clinical imaging of atherosclerosis. Among these PET tracers, inflammation-targeted tracers seem particularly promising. Monocytes, macrophages, and foam cells play important roles in the evolution and complications of atherosclerosis [@B83]. Following their migration to the lesion site, these cells scavenge lipids, secrete cytokines that further amplify inflammation and produce proteases that can be noninvasively visualized with the use of suitable tracers [@B11], [@B83]. The most commonly used PET tracer for imaging of atherosclerosis is ^18^F-FDG, with many other tracers already tested clinically: ^11^C-choline [@B67], ^18^F-galacto-RGD [@B69], ^11^C-acetate [@B74], and ^11^C-PK11195 [@B81]. Since ^11^C-PK11195 specifically binds to macrophages through translocator proteins that are highly expressed on activated macrophages, it may provide more specificity for imaging of atherosclerosis than ^18^F-FDG.

An important contribution of PET imaging of atherosclerosis will be to determine the at-risk individuals earlier in the disease process by targeting one of the abovementioned components at the early stage of disease. It may also prove to be useful in determining the biological responses to certain therapeutic intervention. The key strengths of PET include its excellent sensitivity, limitless depth of penetration, and quantitation capabilities [@B27]. However, the small size of the atherosclerotic lesions and their vicinity with blood, the unbound/circulating tracer activity, and the continuous respiratory and cardiac movements during the acquisition of the images are the unsolved issues in PET imaging of atherosclerosis [@B11], [@B12], [@B84]. The availability of PET/MR systems [@B85], [@B86], where MRI can provide high spatial resolution and exquisite soft tissue contrast to complement PET, may dramatically facilitate the translation of promising PET tracers into the clinic for atherosclerosis imaging.

Measurement of regional and global calcification of the heart and major arteries using ^18^F-NaF PET/CT may also be useful for early detection of atherosclerosis [@B87]. This technique may provide highly relevant information about the state of calcified plaque before structural calcification is detectable by standard CT techniques, thereby allowing for earlier intervention for risk reduction in cardiovascular diseases [@B87], [@B88]. Another potential target for the PET imaging of atherosclerosis is CD105 (i.e. endoglin), where it was demonstrated that precursor atherosclerotic lesions exhibit intimal neovascularization that are associated with increased CD105 expression on endothelial cells [@B89]-[@B91]. In addition, CD105 also plays a role in restenosis after stent placement [@B92], therefore can be used as a marker for the progression of coronary atherosclerosis. We have recently developed a series of CD105-targetted PET and/or optical imaging probes [@B93]-[@B96], which may be applied for PET imaging of atherosclerosis in the near future. In conclusion, PET imaging of atherosclerosis is still at a nascent stage which needs significant future research effort. Smooth clinical translation of promising PET tracers into the clinic is critical to the benefit of patients.
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![The developmental stages of an atherosclerotic lesion. AHA (American Heart Association) stage of the disease is indicated at the bottom of each corresponding column. Adapted from reference [@B6].](thnov03p0894g001){#F1}

![Mac-3 immunostaining of a severely inflamed atherosclerotic plaque. Macrophages are seen in brown, while adventitia and healthy vessel wall areas were Mac-3 negative. L: lumen; P: plaque; W: wall. Adapted from reference [@B79].](thnov03p0894g002){#F2}

![PET imaging of atherosclerosis with various tracers. **A.** Carotid atherosclerotic lesion in a male patient visualized by PET/CT. White arrows show ^18^F-FDG uptake at the level of the plaque in carotid artery. **B.** ^11^C-choline PET/CT images of the aortic arch of a male patient. White arrow indicates the atherosclerotic lesion. **C.** A representative transverse PET slice demonstrating the uptake of ^64^Cu-DOTA-C-ANF on injured (yellow arrow) and control (green arrow) arteries in rabbit femoral artery. F (arrow): fiducial marker. Adapted from references [@B4], [@B67], [@B72].](thnov03p0894g003){#F3}

![Transaxial ^11^C-acetate PET/CT images of abdominal aorta of a male patient. Tracer uptake in vessel wall coincided with calcification in some areas (white arrow), whereas other calcifications of comparable size did not accumulate ^11^C-acetate (white arrow heads). Adapted from reference [@B74].](thnov03p0894g004){#F4}

![PET/CT imaging of inflammatory atherosclerosis in ApoE^-/-^ mice injected with ^64^Cu-TNP. Adapted from reference [@B78].](thnov03p0894g005){#F5}

###### 

Summary of targets and tracers used for PET imaging of atherosclerosis.

  Target                 Tracer                  Preclinical              Clinical
  ---------------------- ----------------------- ------------------------ ---------------------------------------
  Glucose metabolism     ^18^F-FDG               [@B52], [@B53], [@B59]   [@B10], [@B54]-[@B58], [@B60], [@B63]
  Membrane metabolism    ^18^F-choline           [@B65]                   \-
  ^11^C-choline          \-                      [@B67]                   
  Integrin α~v~β~3~      ^18^F-galacto-RGD       [@B68]                   [@B69]
  LDLr                   ^124^I-CD68-Fc-ox-LDL   [@B70]                   \-
  ^18^F-nLDL & ox-LDL    [@B71]                  \-                       
  NPCR                   ^64^Cu-DOTA-C-ANF       [@B72], [@B73]           \-
  Fatty acid synthesis   ^11^C-acetate           \-                       [@B74]
  VCAM-1                 ^18^F-V4                [@B77]                   \-
  Macrophages            ^64^Cu-TNP              [@B78]                   \-
  ^68^Ga                 [@B79]                  \-                       
  ^11^C-PK11195                                  [@B81]                   
  Platelets              ^18^F-AppCHFppA         [@B82]                   \-
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